Based on the seminar materials of the “Oncohematology” Journal Experts Council “Modern approaches to the refractory multiple myeloma treatment”

1. Rustad E.H., Yellapantula V., Leongamornlert D. et al. Timing the initiation of multiple myeloma. Nat Commun 2020;11(1):1917. DOI: 10.1038/s41467-020-15740-9.

2. Sonneveld P., Avet-Loiseau H., Lonial S. et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood 2016;127(24):2955–62. DOI: 10.1182/blood-2016-01-631200.

3. Oliva S., De Paoli L., Ruggeri M. et al. A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma. Ann Hematol 2021;100(2):437–43. DOI: 10.1007/s00277-020-04384-w.

4. Remesh S.G., Santosh V., Escalante C.R. Structural studies of IRF4 reveal a flexible autoinhibitory region and a compact linker domain. J Biol Chem 2015;290(46):27779–90. DOI: 10.1074/jbc.M115.678789.

5. Semochkin S.V. Biological basis of immunomodulatory preparations using in treatment of multiple myeloma. Oncohematology 2010;5(1):21–31. (In Russ.).

6. Cippitelli M., Stabile H., Kosta A. et al. Role of Aiolos and Ikaros in the antitumor and immunomodulatory activity of IMiDs in multiple myeloma: better to lose than to find them. Int J Mol Sci 2021;22(3): 1103. DOI: 10.3390/ijms22031103.

7. Rychak E., Mendy D., Shi T. et al. Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma. Br J Haematol 2016;172(6): 889–901. DOI: 10.1111/bjh.13905.

8. Schey S.A., Fields P., Bartlett J.B. et al. Phase I study of an immunomodulatorythalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 2004;22(16):3269–76. DOI: 10.1200/JCO.2004.10.052.

9. Richardson P.G., Siegel D., Baz R. et al. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood 2013;121(11):1961–7. DOI: 10.1182/blood-2012-08-450742.

10. Lacy M.Q., Allred J.B., Gertz M.A. et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood 2011;118(11):2970–5. DOI: 10.1182/blood-2011-04-348896.

11. San Miguel J., Weisel K., Moreau P. et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, Phase III trial. Lancet Oncol 2013;14(11):1055–66. DOI: 10.1016/S1470-2045(13)70380-2.

12. Pomalidomide. Instructions for medical use. Available at: https://www.rlsnet.ru/mnn_index_id_6668.htm. (In Russ.).

13. Moreau P., Masszi T., Grzasko N. et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2016;374(17):1621–34. DOI: 10.1056/NEJMoa1516282.